Emisphere Technologies (OTC:EMIS) has announced that it has received a recommendation from the Data Monitoring Committee (DMC) to proceed with the Osteoporosis Phase 3 Study 2303, and the Osteoarthritis Phase 3 Study 2301 studying the safety and efficacy of calcitonin to treat patients. The recommendation was based on a futility analysis of date for patients enrolled in a twelve month study. It is the opinion of the DMC that the there are no unexpected safety concerns regarding the treatment.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
Emisphere Technologies, Inc. (Emisphere) is a biopharmaceutical company that focuses on delivery of therapeutic molecules using its eligen technology. The eligen technology can be applied to the oral route of administration, as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The eligen technology is applicable to oral drug delivery technology based on the use of synthetic chemical compounds known as EMISPHERE delivery agents, or carriers. These delivery agents facilitate and enable the transport of therapeutic macromolecules (such as proteins, peptides, and polysaccharides) and poorly absorbed small molecules across biological membranes, such as the small intestine.
Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer
